NCT06341062 The Application of Contrast-enhanced Ultrasound in Acute Kidney Injury in ICU
| NCT ID | NCT06341062 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Third Hospital |
| Condition | Intensive Care Unit |
| Study Type | OBSERVATIONAL |
| Enrollment | 44 participants |
| Start Date | 2024-04-15 |
| Primary Completion | 2025-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 44 participants in total. It began in 2024-04-15 with a primary completion date of 2025-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to quantitatively assess renal microcirculation changes by contrast-enhanced ultrasound and to obtain systemic hemodynamic information by ultrasound Doppler at the same time, to analyze the relationship between renal microcirculation changes and systemic hemodynamic changes, and to explore its predictive value in renal function recovery in patients with critical acute kidney injury. The main questions it aims to answer are: 1. To explore the quantitative parameters of contrast-enhanced ultrasound which can reflect the changes of renal microcirculation. 2. To explore the relationship between renal microcirculation and systemic hemodynamics. 3. To explore the value of renal microflow changes quantitatively evaluated by contrast-enhanced ultrasound in predicting renal function recovery.
Eligibility Criteria
Inclusion Criteria: * Age \>18 years old; * AKI was diagnosed \< 24 hours after first admission to intensive care unit (ICU) and the expected length of stay in ICU ≥48 hours; * Meet Kidney Disease Improving Global Outcomes (KDIGO) 2012 diagnostic criteria for acute kidney injury; * Contrast-enhanced ultrasound was performed within 24 hours after diagnosis of acute kidney injury (AKI). Exclusion Criteria: * Known severe chronic kidney disease (CKD≥ stage 4) or undergoing hemodialysis treatment; * Kidney transplantation or renal malignancy; * Terminal stage of malignant tumor; * Pregnancy; * Renal artery stenosis or renal vein thrombosis; * Allergy to contrast agent SonoVue(BraccoSpA, Milan, Italy) or its components, or the presence of severe cardiopulmonary insufficiency (e.g., right-to-left shunt heart disease or pulmonary systolic blood pressure \>90mmHg).
Contact & Investigator
Ligang Cui, Dr
PRINCIPAL INVESTIGATOR
Department of Ultrasound, Peking University Third Hospital
Frequently Asked Questions
Who can join the NCT06341062 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Intensive Care Unit. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06341062 currently recruiting?
Yes, NCT06341062 is actively recruiting participants. Contact the research team at zhang_yue_wei@126.com for enrollment information.
Where is the NCT06341062 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06341062 clinical trial?
NCT06341062 is sponsored by Peking University Third Hospital. The principal investigator is Ligang Cui, Dr at Department of Ultrasound, Peking University Third Hospital. The trial plans to enroll 44 participants.